Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors |
Journal Updates
eMediNexus Coverage from: 
Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
eMediNexus,  14 May 2022
Coronavirus Live Count Map India

remove_red_eye 553 Views
COVID-19 Vaccine Updates


0 Read Comments                

SGLT2is block the reabsorption of glucose by inhibiting the sodium glucose cotransporter 2 receptor. Hence, these agents improve glucose metabolism by promoting renal excretion of glucose irrespective of insulin secretion.

The advantages of SGLT2is in diabetes include – reduction in body weight; improvement in insulin resistance; glucose homeostasis; and prevention of organ damage. Recent evidence suggests that SGLT2i protects against cardiovascular death, development of HF, as well as the progression of kidney disease. Additionally, SGLT2i effectively lowers the liver fat content and reverses hepatic fibrosis. 

Thus, these drugs confer improvements in multiple organs and provide protection against cardiovascular, renal, and hepatic damage. Their mechanisms underlying organ protection, besides glucose-lowering effects include – improvement of insulin resistance for anti-atherogenesis, osmotic diuresis for cardiac protection, fatty acids utilization for hepatic protection, and improvement of tubuloglomerular feedback for renal protection.

Source: International Journal of Molecular sciences. 2021 Apr 23;22(9):4416.doi: 10.3390/ijms22094416.

To comment on this article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now